Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Myelin Basic Protein (87-99) Mechanisms, Clinical Applicatio

    2025-08-22

    Myelin Basic Protein (87-99): Mechanisms, Clinical Applications, and Research Perspectives in Neuroimmunology

    Introduction
    Myelin Basic Protein (MBP) is a critical structural component of the myelin sheath, which insulates neuronal axons and facilitates rapid signal conduction in the central nervous system (CNS). The MBP (87-99) peptide, a synthetic fragment corresponding to amino acids 87 through 99 of the full-length protein, has emerged as a pivotal research tool in neuroimmunology, particularly in the study of autoimmune demyelinating diseases such as multiple sclerosis (MS) (Pachner & Goverman, 2011, J Neuroimmunol). The MBP (87-99) epitope is recognized as an immunodominant sequence in both human and animal models, capable of inducing experimental autoimmune encephalomyelitis (EAE), a widely used animal model for MS (Miller et al., 2010, Nat Rev Immunol). This paper provides a comprehensive overview of MBP (87-99), detailing its mechanism of action, clinical value, key challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions.

    Mechanism of Action
    MBP (87-99) acts as a potent immunogenic peptide, capable of eliciting T-cell responses that mimic the autoimmune processes observed in MS. Upon administration, MBP (87-99) is processed and presented by antigen-presenting cells (APCs) via major histocompatibility complex (MHC) class II molecules, particularly HLA-DR2 in humans and I-A^u in mice (Wucherpfennig et al., 1995, J Exp Med). This peptide-MHC complex is recognized by autoreactive CD4+ T cells, leading to their activation, proliferation, and subsequent infiltration into the CNS. The resulting inflammatory cascade involves the release of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α), recruitment of additional immune cells, and direct cytotoxicity against oligodendrocytes, culminating in demyelination and neurological deficits (Bettelli et al., 2003, Immunity).

    [Related: Minor component of CNS myelin] Clinical Value and Applications
    The MBP (87-99) peptide holds significant clinical and translational value. Its primary application is in the induction of EAE in susceptible rodent strains, which serves as a robust preclinical model for studying MS pathogenesis, immune mechanisms, and therapeutic interventions (Robinson et al., 2014, Brain Pathol). The reproducibility and immunodominance of MBP (87-99) make it a preferred antigen for dissecting T-cell mediated autoimmunity, evaluating immunomodulatory drugs, and investigating the role of specific cytokines and signaling pathways in CNS inflammation.

    Beyond its use in animal models, MBP (87-99) has been explored as a potential antigenic target in human immunotherapy trials. Peptide-based tolerance induction strategies, such as altered peptide ligands (APLs) or peptide vaccination, aim to modulate autoreactive T-cell responses and restore immune tolerance in MS patients (Kappos et al., 2000, Nat Med). These approaches leverage the immunogenic properties of MBP (87-99) to selectively desensitize pathogenic T cells without broadly suppressing the immune system.

    Key Challenges and Pain Points Addressed
    Current treatments for MS primarily focus on broad immunosuppression or modulation, which can lead to increased susceptibility to infections and malignancies (Hauser & Cree, 2020, N Engl J Med). There is a critical need for antigen-specific therapies that target pathogenic immune responses while preserving overall immune competence. MBP (87-99) addresses several key challenges:
    1. **Modeling Disease Pathogenesis:** The peptide enables precise recapitulation of T-cell mediated demyelination, facilitating mechanistic studies that are not possible with non-antigen-specific models.
    2. **Therapeutic Screening:** MBP (87-99)-induced EAE models provide a platform for preclinical testing of novel immunotherapies, including monoclonal antibodies, cytokine inhibitors, and peptide-based vaccines.
    3. **Antigen-Specific Tolerance:** By serving as a defined autoantigen, MBP (87-99) supports the development of targeted tolerance-inducing strategies, potentially reducing off-target effects and improving safety profiles.
    4. **Biomarker Discovery:** The immune response to MBP (87-99) can be used to identify biomarkers of disease activity, progression, and therapeutic response.

    [Related: semaxanib] Literature Review
    A substantial body of literature underpins the scientific utility and translational potential of MBP (87-99):
    1. **Wucherpfennig et al. (1995, J Exp Med):** This seminal study identified MBP (87-99) as an immunodominant epitope recognized by T cells in MS patients, highlighting its relevance in human disease.
    2. **Bettelli et al. (2003, Immunity):** Demonstrated that MBP (87-99)-specific T cells are sufficient to induce EAE and characterized the cytokine profiles associated with disease severity.
    3. **Robinson et al. (2014, Brain Pathol):** Reviewed the use of MBP (87-99)-induced EAE models in preclinical drug development, emphasizing their predictive value for human MS.
    4. **Kappos et al. (2000, Nat Med):** Reported the first clinical trial of an altered peptide ligand based on MBP (87-99) in MS patients, providing proof-of-concept for antigen-specific immunotherapy.
    5. **Miller et al. (2010, Nat Rev Immunol):** Provided a comprehensive overview of EAE models, with a focus on the role of MBP (87-99) in dissecting T-cell and cytokine networks.
    6. **Pachner & Goverman (2011, J Neuroimmunol):** Discussed the translational relevance of MBP (87-99)-induced EAE for understanding MS pathogenesis and testing novel therapeutics.
    7. **Hauser & Cree (2020, N Engl J Med):** Reviewed current MS therapies, underscoring the limitations of non-specific immunosuppression and the need for antigen-specific approaches.

    Experimental Data and Results
    Experimental studies utilizing MBP (87-99) have yielded critical insights into the immunopathology of MS and the efficacy of emerging therapies. In the classic EAE model, susceptible mouse strains (e.g., C57BL/6, SJL/J) are immunized with MBP (87-99) emulsified in complete Freund’s adjuvant (CFA), often with pertussis toxin as an adjuvant to enhance blood-brain barrier permeability (Bettelli et al., 2003, Immunity). Disease onset typically occurs within 10–14 days post-immunization, characterized by ascending paralysis, weight loss, and histological evidence of CNS demyelination and inflammatory infiltrates.

    Key findings from MBP (87-99)-induced EAE studies include:
    - **T-cell Activation:** MBP (87-99) elicits robust CD4+ T-cell proliferation and cytokine production, with a predominance of Th1 and Th17 phenotypes driving CNS inflammation (Miller et al., 2010, Nat Rev Immunol).
    - **Cytokine Modulation:** Therapeutic interventions targeting IL-17, IFN-γ, or TNF-α pathways have demonstrated efficacy in reducing disease severity in MBP (87-99)-induced EAE (Robinson et al., 2014, Brain Pathol).
    - **Tolerance Induction:** Administration of MBP (87-99) via mucosal or intravenous routes can induce antigen-specific tolerance, attenuating EAE symptoms and reducing CNS pathology (Kappos et al., 2000, Nat Med).
    - **Drug Screening:** Numerous immunomodulatory agents, including fingolimod, natalizumab, and anti-CD20 antibodies, have been validated in MBP (87-99) EAE models prior to clinical translation (Hauser & Cree, 2020, N Engl J Med).

    Collectively, these data underscore the utility of MBP (87-99) as a versatile tool for elucidating disease mechanisms and evaluating therapeutic efficacy in preclinical settings.

    [Related: navitoclax] Usage Guidelines and Best Practices
    The effective use of MBP (87-99) in experimental and translational research requires adherence to established protocols and consideration of key variables:
    - **Peptide Preparation:** MBP (87-99) should be synthesized to high purity (>95%) and reconstituted in sterile, endotoxin-free water or buffer. Peptide aliquots should be stored at -20°C to maintain stability.
    - **Animal Models:** Selection of appropriate rodent strains (e.g., SJL/J for relapsing-remitting EAE, C57BL/6 for chronic EAE) is critical. Immunization protocols typically involve subcutaneous injection of 100–200 µg MBP (87-99) emulsified in CFA Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 59 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11487196